Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
Amino Acid Sequence
Animals
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cell Line, Tumor
Cell-Penetrating Peptides
/ administration & dosage
Drug Resistance, Neoplasm
/ drug effects
Drug Screening Assays, Antitumor
Drug Synergism
Female
Genes, myc
Humans
Inhibitory Concentration 50
Leucine Zippers
/ genetics
Mice
Models, Molecular
Molecular Targeted Therapy
/ methods
Mutation
Neoplasm Proteins
/ antagonists & inhibitors
Peptide Fragments
/ administration & dosage
Peptide Library
Protein Conformation
Protein Engineering
Proto-Oncogene Proteins c-myc
/ administration & dosage
Recombinant Fusion Proteins
/ administration & dosage
Triple Negative Breast Neoplasms
/ drug therapy
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
03
12
2017
accepted:
29
06
2018
revised:
24
05
2018
pmc-release:
03
02
2019
pubmed:
5
8
2018
medline:
12
3
2019
entrez:
5
8
2018
Statut:
ppublish
Résumé
Overexpression of MYC oncogene is highly prevalent in many malignancies such as aggressive triple-negative breast cancers (TNBCs) and it is associated with very poor outcome. Despite decades of research, attempts to effectively inhibit MYC, particularly with small molecules, still remain challenging due to the featureless nature of its protein structure. Herein, we describe the engineering of the dominant-negative MYC peptide (OmoMYC) linked to a functional penetrating 'Phylomer' peptide (FPPa) as a therapeutic strategy to inhibit MYC in TNBC. We found FPPa-OmoMYC to be a potent inducer of apoptosis (with IC
Identifiants
pubmed: 30076412
doi: 10.1038/s41388-018-0421-y
pii: 10.1038/s41388-018-0421-y
pmc: PMC6318000
mid: NIHMS979334
doi:
Substances chimiques
Cell-Penetrating Peptides
0
FPPa peptide
0
MYC protein, human
0
Neoplasm Proteins
0
Peptide Fragments
0
Peptide Library
0
Proto-Oncogene Proteins c-myc
0
Recombinant Fusion Proteins
0
omomyc protein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
140-150Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM104318
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA170370
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA036906
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM112722
Pays : United States
Références
Clin Breast Cancer. 2017 Jun;17(3):188-194
pubmed: 28089283
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Cancer Res. 2011 Aug 1;71(15):5164-74
pubmed: 21646475
Nat Commun. 2017 Jan 09;8:13923
pubmed: 28067227
Mol Cancer Ther. 2005 Jul;4(7):1076-85
pubmed: 16020665
Br J Cancer. 2016 Apr 12;114(8):917-28
pubmed: 26954716
Oncogene. 1998 Nov 12;17(19):2463-72
pubmed: 9824157
J Cell Biol. 2006 Jan 2;172(1):139-49
pubmed: 16391002
Oncogene. 2017 Apr 6;36(14):1911-1924
pubmed: 27748763
Mol Cell Biol. 1999 Jul;19(7):4672-83
pubmed: 10373516
Nat Med. 2016 Apr;22(4):427-32
pubmed: 26950360
Leuk Res. 2015 Jul;39(7):730-8
pubmed: 25916698
Science. 2002 Jul 5;297(5578):102-4
pubmed: 12098700
Methods Mol Biol. 2012;899:43-60
pubmed: 22735945
Nature. 2016 Jan 21;529(7586):413-417
pubmed: 26735014
Cancer Res. 1998 Aug 15;58(16):3654-9
pubmed: 9721875
PLoS One. 2011;6(7):e22284
pubmed: 21811581
Mol Cancer Ther. 2016 May;15(5):1018-28
pubmed: 26908627
Clin Cancer Res. 2011 Apr 1;17(7):2024-34
pubmed: 21346144
Clin Cancer Res. 2017 Feb 1;23(3):649-657
pubmed: 27301700
Oncogene. 1995 Jul 6;11(1):175-9
pubmed: 7624125
Cell Metab. 2017 Oct 3;26(4):633-647.e7
pubmed: 28978427
Biochem Pharmacol. 2006 Jan 12;71(3):248-56
pubmed: 16316634
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Cell Death Differ. 2004 Sep;11(9):1038-45
pubmed: 15143346
Breast Cancer Res. 2010;12(5):R68
pubmed: 20813035
J Clin Oncol. 1989 May;7(5):560-71
pubmed: 2468745
Genome Biol. 2003;4(10):R69
pubmed: 14519204
Clin Cancer Res. 2004 Aug 15;10(16):5367-74
pubmed: 15328174
Sci Rep. 2015 Nov 13;5:15494
pubmed: 26563484
Clin Cancer Res. 2008 Dec 1;14(23):7878-83
pubmed: 19047117
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Cell Rep. 2016 Aug 2;16(5):1273-1286
pubmed: 27452461
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9
pubmed: 12808131
Nat Biotechnol. 2006 Feb;24(2):177-83
pubmed: 16465163
Clin Cancer Res. 2004 Jan 15;10(2):499-507
pubmed: 14760071
Curr Opin Chem Biol. 2017 Jun;38:127-133
pubmed: 28528024
Genes Dev. 2002 Oct 1;16(19):2530-43
pubmed: 12368264
J Exp Med. 2012 Apr 9;209(4):679-96
pubmed: 22430491
EMBO Rep. 2016 Dec;17(12):1872-1889
pubmed: 27852622
Oncogene. 2003 Sep 18;22(40):6151-9
pubmed: 13679853
Genes Dev. 2013 Mar 1;27(5):504-13
pubmed: 23475959
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25
pubmed: 18509642
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12556-61
pubmed: 25114221
PLoS One. 2014 Aug 15;9(8):e105381
pubmed: 25127121
Elife. 2016 Jul 27;5:
pubmed: 27460974
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5425-30
pubmed: 25870263
Cell Rep. 2015 Apr 21;11(3):390-404
pubmed: 25865888
J Natl Cancer Inst. 2014 Oct 11;106(12):
pubmed: 25306215
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3830-5
pubmed: 11891322
Biochim Biophys Acta. 2015 May;1849(5):525-43
pubmed: 24657798
Future Med Chem. 2009 May;1(2):257-65
pubmed: 21425969
Oncogene. 2014 Sep 25;33(39):4767-77
pubmed: 24141779
Clin Cancer Res. 2012 Oct 1;18(19):5290-303
pubmed: 22872574
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4558-66
pubmed: 27432991
Breast Cancer Res. 2008;10(1):R10
pubmed: 18241344
Sci Rep. 2015 Dec 16;5:18329
pubmed: 26671759
Nat Commun. 2014 Aug 18;5:4632
pubmed: 25130259
Clin Cancer Res. 2015 Mar 1;21(5):995-1001
pubmed: 25501126
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3698-703
pubmed: 20133671
Mol Cancer Ther. 2007 Sep;6(9):2399-408
pubmed: 17876039
Lancet Haematol. 2016 Apr;3(4):e186-95
pubmed: 27063977
Science. 1991 Mar 8;251(4998):1211-7
pubmed: 2006410
Science. 1992 Jul 10;257(5067):212-4
pubmed: 1378649
Cancer Res. 2002 Jun 15;62(12):3507-10
pubmed: 12067996
Cancer Cell. 2015 Jun 8;27(6):837-51
pubmed: 26058079
Nat Rev Cancer. 2017 Aug;17(8):502-508
pubmed: 28643779
Nanoscale. 2016 Apr 28;8(17):9343-53
pubmed: 27089946
J Pharmacol Exp Ther. 2010 Dec;335(3):715-27
pubmed: 20801893
Front Cell Dev Biol. 2017 Feb 23;5:10
pubmed: 28280720
Clin Cancer Res. 1999 Sep;5(9):2588-95
pubmed: 10499637
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544